Overview

TGF-β And PDL-1 Inhibition in Esophageal Squamous Cell Carcinoma Combined With Chemoradiation TheRapY

Status:
Recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to assess the feasibility of treatment with bintrafusp alfa combined with definitive chemoradiation (carboplatin, paclitaxel and radiation) in patients with squamous cell carcinoma of the esophagus or gastroesophageal junction.
Phase:
N/A
Details
Lead Sponsor:
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Collaborators:
Catharina Ziekenhuis Eindhoven
Deventer Ziekenhuis
Elisabeth-TweeSteden Ziekenhuis
Erasmus Medical Center
Isala
Leiden University Medical Center
Maastro Clinic, The Netherlands
Medisch Centrum Leeuwarden
Radiotherapeutic Institute Friesland
Radiotherapy Group Deventer
Rijnstate Hospital
The Netherlands Cancer Institute
UMC Utrecht
University Medical Center Groningen
Verbeeten Insituut Tilburg
ZGT
Zuyderland Medisch Centrum
Treatments:
Carboplatin
Paclitaxel